NNNN
Anbio Biotechnology Class A Ordinary Shares
NNNN
NNNN
5 hedge funds and large institutions have $937K invested in Anbio Biotechnology Class A Ordinary Shares in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
5
Holders Change
+2
Holders Change %
+66.67%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
UBS Group
Zurich,
Switzerland
|
+$157K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$39.9K |
| 3 |
Morgan Stanley
New York
|
+$12.7K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$3.17K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.22K |
Top Sellers
| 1 |
Marshall Wace
London,
United Kingdom
|
-$325K |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $542K | +$2.22K | +70 | +0.4% |
|
|
2
UBS Group
Zurich,
Switzerland
| $339K | +$157K | +4,957 | +86% |
|
|
3
BNP Paribas Financial Markets
Paris,
France
| $39.9K | +$39.9K | +1,261 | New |
|
|
4
Morgan Stanley
New York
| $12.7K | +$12.7K | +400 | New |
|
|
5
Wells Fargo
San Francisco,
California
| $3.17K | +$3.17K | +100 | New |
|
|
6
Marshall Wace
London,
United Kingdom
| – | -$325K | -43,629 | Closed |
|